Coherus BioSciences Inc Asset Resilience Ratio
Coherus BioSciences Inc asset resilience ratio. Coherus BioSciences Inc (CHRS) has an Asset Resilience Ratio of 11.71% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Coherus BioSciences Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Coherus BioSciences Inc (2012–2025)
Asset resilience ratio of Coherus BioSciences Inc from 2012 to 2025. This chart shows how Coherus BioSciences Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Coherus BioSciences Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Coherus BioSciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Coherus BioSciences Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.38 Million | 11.71% |
| Total Liquid Assets | $22.38 Million | 11.71% |
Asset Resilience Insights
- Moderate Liquidity: Coherus BioSciences Inc has 11.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Coherus BioSciences Inc Industry Peers by Asset Resilience Ratio
Compare Coherus BioSciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Coherus BioSciences Inc Asset Resilience Ratio by Year (2012–2025)
Coherus BioSciences Inc asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Coherus BioSciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.22% | $83.25 Million | $258.34 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $448.53 Million | -- |
| 2023-12-31 | 2.36% | $14.86 Million | $629.60 Million | -24.29pp |
| 2022-12-31 | 26.65% | $128.13 Million | $480.85 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $679.33 Million | -- |
| 2017-12-31 | 0.04% | $60.00K | $162.61 Million | +0.00pp |
| 2016-12-31 | 0.03% | $60.00K | $178.49 Million | +0.01pp |
| 2015-12-31 | 0.03% | $60.00K | $212.38 Million | 0.00pp |
| 2014-12-31 | 0.03% | $60.00K | $187.22 Million | -0.07pp |
| 2013-12-31 | 0.11% | $50.00K | $47.45 Million | -0.08pp |
| 2012-12-31 | 0.19% | $50.00K | $26.53 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more